Integrated behavioral treatment for Veterans with co-morbid chronic pain and hazardous opioid use: A randomized controlled pilot trial


Published in:
The Journal of Pain

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person’s rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Open Access
This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: http://go.qub.ac.uk/oa-feedback
Integrated behavioral treatment for Veterans with co-morbid chronic pain and hazardous opioid use: A randomized controlled pilot trial

Kevin E. Vowles, PhD
Katie Witkiewitz, PhD
Karen J. Cusack, PhD
Wesley P. Gilliam, PhD
Karen E. Cardon, MD
Sarah Bowen, PhD
Karlyn A. Edwards, MS
Mindy L. McEntee, PhD
Robert W. Bailey, PhD

1 School of Psychology, Queen’s University Belfast
2 Department of Psychology, University of New Mexico
3 Raymond G. Murphy Veteran’s Affairs Medical Center, New Mexico VA Healthcare System
4 Pain Rehabilitation Center, Mayo Clinic
5 Department of Psychology, Pacific University
6 College of Health Solutions, Arizona State University, Tempe, AZ, USA
7 Swedish Pain Services, Swedish Health System, Seattle, WA, USA

06 November 2019

Correspondence to: Kevin E. Vowles, PhD, School of Psychology, Queen’s University Belfast, David Keir Building, 18-30 Malone Rd, Belfast BT9 5BN, Northern Ireland, United Kingdom.

Keywords: Chronic Pain, Opioids, Veterans, integrated treatment, Acceptance and Commitment Therapy, Mindfulness-Based Relapse Prevention

Funding: This work was supported by funding from the National Center for Complementary and Integrative Health (R34 AT08398, Vowles, PI).
Abstract

Opioid prescription in the treatment of chronic pain is frequent and carries a risk of increased morbidity and mortality in a clinically significant number of patients, particularly those who are using opioids in a hazardous manner. Few treatment options are available that target both pain-related interference and hazardous opioid use among patients with chronic pain. In military Veterans, this issue is of particular importance as numerous reports indicate continued high rates of opioid prescription for chronic pain, as well as significant opioid-related problems. The overall aim of the present study was to determine the feasibility of an integrated psychosocial treatment in Veterans with chronic pain, who also have evidence of hazardous opioid use. To examine this aim, a random design was used to assess the feasibility and initial efficacy of integrating two empirically supported interventions: Acceptance and Commitment Therapy for chronic pain and Mindfulness Based Relapse Prevention for opioid misuse. Half of participants were randomized to the integrated treatment group and all participants received usual care (UC) through a Veteran’s Administration co-occurring disorders medical clinic to treat chronic pain and opioid misuse. In total, 37 participants were randomized and included in intent to treat (ITT) analyses and 32 individuals were included in per protocol (PP) analyses with 6-month follow-up serving as the primary study endpoint. Feasibility indicators included recruitment, retention, and treatment completion rates. Recruitment fell short of targeted enrollment, although retention and completion were excellent. Primary outcome measures were opioid misuse, pain interference, and pain behavior. Simultaneous multiple regression analyses controlled for pain duration, baseline opioid dose, and baseline value for outcome measures. Results of both the ITT and PP indicated a significant effect in favor of the integrated intervention for opioid misuse, pain interference, and pain behavior. Results support the feasibility of providing an integrated treatment for both opioid risk and pain interference.

Perspective: Opioid misuse occurs in some opioid-prescribed individuals with chronic pain. Few treatment options exist that target both pain interference and opioid misuse. This study
examined feasibility and initial efficacy of an integrated behavioral treatment for Veterans. Feasibility was supported, except recruitment. Efficacy was supported compared to usual care.
Introduction

Chronic pain, defined as pain that persists longer than three months, is common, costly, and debilitating\textsuperscript{10,26,35,50}. The preponderance of the available evidence suggests that problems associated with chronic pain have been exacerbated by exponential increases in prescribed opioids over the past few decades\textsuperscript{3,4}. Overall opioid prescription rates have doubled in this century, from 11\% to 20\% of all pain-related ambulatory and office-based medical visits, while overall rates of pain as a primary symptom and prescription rates of non-opioid analgesics remained unchanged\textsuperscript{16}.

While prescription rates have decreased moderately over the past few years, rates remained approximately 300\% higher in 2016 compared to 2006\textsuperscript{13,54}. Furthermore, significant adverse consequences related to opioids remain, with the January 4, 2019 edition of the Center for Disease Control’s \textit{Morbidity and Mortality Weekly Report}\textsuperscript{48} indicating continued increases in opioid-related mortality in 2017, with a total of 47,600 overdose deaths. The adverse impact of aberrant opioid use is widespread enough in the United States (US) that it is now considered a public health crisis. In chronic pain patients, hazardous opioid use appears to occur in a clinically significant proportion of patients\textsuperscript{23,37,59}.

In US military Veterans, the issues of chronic pain and opioid-related problems are more pronounced than in non-Veterans. Chronic pain is common, distressing, and debilitating, particularly in those that have served since the first Gulf War, with prevalence estimates reaching as high as 68\%\textsuperscript{15,28,31,36,51}. As in civilian healthcare settings, opioids were increasingly used in Veteran healthcare settings for the treatment of chronic pain during the early part of this century\textsuperscript{15,41,49}. While the Veterans Affairs (VA) Opioid Safety Initiative\textsuperscript{52} and other efforts have led to decreasing prescription rates, the most recent 2018 VA Opioid Prescribing Data indicate that high rates of opioid prescribing remains a significant problem in the VA\textsuperscript{70}. Furthermore, there is evidence of a vicious cycle of comorbidity amongst chronic pain, opioid misuse (i.e., using not as prescribed), and adverse events in Veterans\textsuperscript{20,46}. For example, a chronic pain
diagnosis increase the risk for prescription drug misuse and opioid prescription for chronic pain increases risk of adverse clinical outcomes (e.g., accidents resulting in wounds, opioid-related accidents, overdose, violence-related injuries) in a manner independent of mental health diagnoses or other prescribed medications. Clinicians in VA hospitals are well aware of these issues and have noted both frustration and uncertainty in treating persons with chronic pain, as well as the lack of evidence-based approaches that simultaneously treat problems related to both chronic pain and opioid misuse.

Given the combined prevalence, cost, and disruptive nature of both chronic pain and problematic opioid use, particularly in Veterans, a crucial healthcare objective at present involves the identification of coordinated and efficacious treatments for patients with both chronic pain and opioid use disorder (OUD). Such treatments will need to simultaneously reduce both the problematic interference of chronic pain on functioning and problematic opioid use. While previous work has been shown to reduce opioid misuse behaviors in those with chronic pain, there are only a handful of interventions that have targeted both pain interference and hazardous opioid use in a coordinated fashion. Two recent studies incorporating cognitive behavioral treatment (CBT) for substance use disorders with medication assisted treatment for opioid-treated chronic pain failed to have a significant effect on pain interference. Naylor et al. used an Interactive Voice Response system as a follow-on to CBT for chronic pain and found it to have beneficial effect on both analgesic consumption and disability in comparison to no follow-up, although they did not measure opioid misuse specifically. To our knowledge, the only example of a successful integrated intervention are two trials by Garland and colleagues, who found that Mindfulness-Oriented Recovery Enhancement (MORE) successfully reduced pain interference and opioid misuse in comparison to a support group control. Of note, participants in these trials did not have to present with evidence of opioid misuse for inclusion, and the latter trial specifically excluded these individuals.
There is clearly a need to examine interventions suitable for people with chronic pain who are presently using opioids in a hazardous manner. Integration of treatments that have shared theoretical frameworks and focus on adaptive behavior change may be both feasible and efficacious for chronic pain and opioid misuse. Two candidate interventions for integration include Acceptance and Commitment Therapy for chronic pain and Mindfulness-Based Relapse Prevention for opioid misuse. These two interventions are excellent candidates for integration for several reasons. First, they each have evidence of effect. In those with chronic pain, ACT is effective at reducing pain interference and MBRP has established effectiveness in substance use disorder populations. Second, these two interventions come from a shared theoretical background, where the primary purposes of treatment include altering response to aversive experiences to allow for better functioning over the longer term. For example, ACT seeks to improve adaptive responses to the pain experience by increasing willingness to have pain in the service of valued life domains. Relatedly, MBRP seeks to alter response to substance cravings. Third, both interventions share an emphasis on the cultivation of present-focused awareness and willingness to have present experiences as a manner of achieving adaptive responding to pain and cravings specifically. The present study sought to test the feasibility and initial efficacy of an integrated treatment that combined ACT and MBRP to address opioid misuse, pain interference, and pain behavior in among Veterans with chronic pain who were prescribed opioids. Participants were randomized to one of two treatment arms: (1) physician care through a co-occurring disorders clinic for patients with chronic pain and evidence of opioid misuse (usual care; UC) or (2) the integrated treatment plus UC. Each group was followed for twelve weeks during the active intervention phase and the primary study endpoint was a 6-month follow-up appointment.

**Methods**

*Participants*
To be eligible for study inclusion, participants were required to be receiving treatment for chronic pain through the Albuquerque Veteran’s Affairs Medical Center, be prescribed at least one opioid medication for the treatment of chronic pain, and show evidence of current opioid misuse. Opioid misuse was defined as at least one of the following: a score on the Current Opioid Misuse Measure (COMM) in excess of the established cut point of 9 or greater and/or meeting criteria for opioid use disorder (OUD) using the Structured Clinical Interview for DSM 5 (SCID). Participants also had to speak and read English and consent to randomization. Exclusion criteria included history of suicide attempt in the preceding 12 months, current buprenorphine prescription, or evidence of uncontrolled psychosis. All participants referred to the study were asked to complete a telephone screening, which provided study details and entailed an initial assessment in relation to inclusion criteria. Those who passed the phone screen were invited for an in-person screening session, where they completed the SCID, study questionnaires, and informed consent. Randomization occurred following this baseline assessment. A block randomization method was used with a block size of four. This study was registered with clinicaltrials.gov (NCT02423772). This study was approved by both VA and University Institutional Review Boards.

**Integrated Intervention**

A twelve-session treatment protocol was constructed using the methods described in other established protocols for ACT and MBRP. The study team are primary developers of ACT for chronic pain (KEV) and MBRP for substance use disorders (KW, SB). These individuals facilitated the training of study clinicians (MLM, RWB, KAE).

Sessions were held weekly for 90 minutes each, with every session including content from both ACT and MBRP, such that responses to pain and opioid craving were discussed during each session. Appendix 1 details the content of each session. In brief, the primary treatment objectives of ACT for chronic pain were to decrease pain’s interference on functioning, particularly with regard to meaningful activities. Treatment included exposure-
Integrated treatment

Based exercises, skills training, and behavioral experimentation designed to augment willingness and acceptance of pain, develop persistence and flexibility in the pursuit of behavioral goals, and increase effective responding to pain. Further, MBRP was designed to target experiences of craving and substance use. Intervention included skills training in relapse prevention (e.g., coping skills training) and in mindfulness meditation. The mindfulness practices were intended to increase awareness and acceptance, with a specific focus on uncomfortable or unwanted experiences related to substance use. The practices teach clients to observe discomfort (including pain) without judgement and without engaging in an automatic or habitual reaction. Treatment was provided in a group format with a minimum group size of four participants.

Usual Care. All participants received physician directed care through a VA co-occurring disorders clinic that primarily provided medical oversight of opioid prescription and directed patients to other necessary pain interventions. For all participants, UC interventions were guided by the treatment plan and not manipulated by the research team. Consistent with national and VA standards, care typically consisted of noninvasive interventions, such as analgesic pain medications (e.g., opioids, NSAIDs, anti-epileptics), topical solutions (e.g., lidocaine), physical therapy, and massage, as well as limited invasive interventions (e.g., injections, radiofrequency denervation).

Measures

Feasibility. The feasibility of offering an integrated intervention for co-morbid chronic pain and opioid misuse was evaluated via three primary indicators. The first was feasibility of recruitment. We planned to randomize 120 individuals to the study. We aimed to randomize 80% of individuals meeting study inclusion and exclusion criterion. Second, we assessed feasibility of retention by evaluating treatment attrition. Given the results of other behavioral treatments for chronic pain, we expected an attrition rate of 20%. Finally, we assessed
both session attendance rates and individual participant attendance rates. For both of these latter measures, we counted adequate attendance as 75% or greater.

**Therapist adherence.** All study therapists completed a multi-day workshop in ACT and MBRP and were doctoral trainees in a clinical psychology program. All clinical sessions were audiotaped and reviewed in full for adherence to protocol by the senior author (KEV), who also met with study therapists weekly for clinical supervision. It was planned that any therapist demonstrating poor adherence to the protocol would repeat the training workshops to ensure fidelity to the intervention.

**Treatment outcome.** Primary outcome measures were risk of hazardous opioid use, as assessed by the COMM\textsuperscript{12}, pain interference, as measured by PROMIS short form 8a\textsuperscript{2}, and pain behavior, as measured by the PROMIS V1.1 short form 7a\textsuperscript{47}. The COMM is a 17-item measure designed to aid in the identification of opioid misuse. Scores range from 0 – 68 with higher scores indicating greater risk of misuse. As noted, a cut score of 9 or greater was used to identify the presence of opioid misuse. The PROMIS pain interference assesses the impact of pain on important aspects of social, physical, cognitive, and recreational activities. It consists of eight items and scores range from 8 to 40 with higher scores indicating greater pain interference. The PROMIS pain behavior measures self-reported frequency of verbal and nonverbal behaviors indicating that one is experiencing pain. It consists of seven items with scores ranging from 7 to 35 with higher scores indicating more frequent pain behavior.

There were two secondary outcomes analyzed. First, prescribed opioid dose was extracted from medical records and converted to morphine milligram equivalent dose (MED) per day. Second, usual pain intensity over the preceding seven days was assessed via a 0 (no pain) – 10 (worst pain possible) numerical rating scale.

**Analytic Approach**

For measures of adherence, we calculated study drop-out rates and, for those randomized to the integrated intervention, session attendance rates, and percent of participants
who completed treatment (75% or greater session attendance). Therapist protocol adherence was also calculated as a percent adherence to session content.

Intent-to-treat (ITT) and per protocol analyses were conducted using simultaneous linear regression equations, where follow-up score for each outcome was regressed onto baseline outcome score and group membership. Data management were performed using SPSS version 25.0\textsuperscript{33}, as was calculation of descriptive information. Simultaneous regression analyses used Mplus version 8.1\textsuperscript{42} using maximum likelihood estimation. Maximum likelihood estimation is a preferred method for missing data handling, assuming data are missing at random. To control for any effects of treatment cohort, a weighted maximum likelihood function with robust standard errors was computed using a sandwich estimator (i.e., standard errors were adjusted for cohort membership in the data).

Results

Participants. Participants were primarily male (86%) with relationship status split fairly evenly across three categories, including married/cohabitating (39%), single (32%), and divorced/separated (29%). Ethnically, participants identified as non-Hispanic white (51.4%), Latinx (28.6%), Native American (17.1%), and other (2.9%). Years of education averaged 14.5 (SD: 2.1) with identified categories of educational achievement including, “some college” (57.1%), college degree (14.3%), technical/trade school degree (11.4%), high school degree (14.3%), and post-graduate degree (2.9%). All participants were unemployed, with the largest proportion of participants retired or not working due to pain (78.1%), and the remainder of individuals not working due to reasons unrelated to pain.

Across randomized participants, pain duration averaged 17.2 years (SD: 8.7). Primary pain location included low back (65.7%), leg/hip (14.3%), whole body (11.4%), and neck (8.6%). Secondary pain locations were reported by 85.7% of participants. Regarding compensation status, participants were receiving social security disability (57.1%), VA service connection (51.4%), and other (e.g., workers compensation; 5.7%).
Feasibility. Figure 1 displays participant flow throughout the study. With regard to feasibility of recruitment, 115 individuals in total were referred to the study, of which 85 completed a phone screening. Forty-two individuals completed the in-person screen. Of these, 35 individuals met inclusion criteria and consented to randomization with 17 randomized to the integrated treatment and 18 randomized to UC. In total, 28 of these individuals, 80%, began the allocated treatment, with 88.2% and 72.0% beginning the integrated intervention and UC only arm, respectively. Of those who began the allocated intervention, 78.6% provided data at 6-month follow-up, including 80.0% and 76.9% completion rates for the integrated intervention and UC only arms, respectively.

Of the 15 patients who began the integrated intervention arm, total treatment attendance across all 12 sessions was 77%. One participant attended only the first session; average attendance was 82% after excluding this individual. Thirteen participants had attendance rates in excess of 75% (i.e., 9+ sessions) with the remaining two individuals attending 8% (1 session) and 17% (2 sessions). Both of these latter individuals dropped out of treatment.

In total, four treatment groups were conducted. Treatment group size ranged from four to six. All groups ended with at least three participants. Three therapists were trained in the study protocol. Following full review of audio recordings of each therapy session, adherence rates to the protocol were rated as high, at 96%. Specifically, therapists provided the necessary components of treatment and the specific interventions identified at each session with high fidelity.

Outcomes analyses. Table 1 displays demographic and baseline measure details for randomized individuals. At baseline, no group differences were indicated for any variable with the sole exception of prescribed MED. For this variable, the integrated intervention group began treatment with a higher prescribed daily MED dose in comparison to the UC group, $F (1, 34) = 6.9, \ p = .01$. Boxplot inspection indicated three participants had MED values that were outliers. All three participants were randomized to the integrated treatment condition and had MED
values of 318, 300, and 240 per day. A Winsorizing procedure replaced the outlying MED values for these three participants with the value of the next non-outlying MED values, which was 180 per day, and another ANOVA using the Winsorized data was conducted, which continued to indicate a significant between group difference, $F(1, 34) = 7.1, p = .01$. Therefore, primary outcome analyses used MED as a covariate. Two of the participants with outlying baseline MED data completed follow-up and their raw (i.e., non-Winsorized) baseline values were used in outcome analyses to ensure accurate reporting of any change in MED.

As noted above, 35 individuals were randomized, of which 28 began the allocated intervention, and 22 completed 6-month follow-up. No baseline differences were indicated between participants who dropped out after randomization and who completed follow-up, all $Fs < 3.3$, all $ps > .08$, with the sole exception of pain duration for which there was a significant between group difference indicated, $F(1, 34) = 5.9, p = .02$. Individuals who dropped out reported shorter average pain duration, 12.1 years ($SD = 6.9$), than those who completed follow-up, 18.7 years ($SD = 8.4$). Given this difference, pain duration was used as a covariate in all regression analyses.

With regard to primary outcome measures, simultaneous regression analyses were performed regressing follow-up values for primary and secondary outcome measures onto baseline values for the measures, prescribed MED, pain duration, and group membership. Standardized beta-weights and unstandardized betas were calculated, as was variance for each model.

Table 2 displays both ITT and per protocol results. In the case of four of five outcomes, including current opioid misuse, pain interference, pain behavior, and usual pain intensity in the past week, treatment group accounted for significant variance in 6-month values. In each case, membership in the integrated intervention group was associated with lower scores on each outcome. For prescribed MED, treatment group membership did not account for significant variance in follow-up dose.
Table 3 presents descriptive information for all outcomes for each treatment group. For current opioid misuse, COMM scores for the UC group remained fairly stable across the two assessment points, while the score decreased for the integrated intervention group. All patients had baseline COMM scores in excess of the recommended cut-point of nine or above\textsuperscript{12}. At follow-up, six individuals (50\%) in the integrated intervention group and one individual (10\%) in the UC group had COMM scores that were below this cutoff. The effect size difference between the integrated intervention and UC at follow-up indicated a medium-to-large effect size of the integrated intervention on COMM scores ($d = .73$).

For both pain interference and usual pain intensity, scores for the integrated intervention group decreased while scores for the UC group increased between baseline and follow-up with large effect size differences between groups at follow-up (pain interference: $d = .79$; pain intensity: $d = 1.08$). For Pain Behavior, scores in the integrated intervention group reduced modestly and stayed steady in UC, with a small between group effect size at follow-up ($d = .30$). Prescribed Opioid Dose decreased over this same time period for both groups and the integrated intervention had a higher prescribed opioid dose at both baseline and follow-up ($d = .83$).

Discussion

A clinical pilot study was conducted to examine the feasibility and initial efficacy of an integrated behavioral treatment for co-morbid chronic pain and opioid misuse. In total, 35 Veterans were randomized, with 28 included in per protocol analyses. Two evidence-based interventions were utilized in the integrated treatment group, Acceptance and Commitment Therapy (ACT) for chronic pain and Mindfulness-Based Relapse Prevention (MBRP) for substance misuse. All individuals received usual care (UC) of physician directed treatment though a specialized clinic to address chronic pain and opioid misuse. In addition to assessing feasibility of recruitment and retention, primary outcomes were opioid misuse, pain interference, and pain behavior. All participants evidenced opioid misuse behaviors, as indicated by baseline
COMM scores, and all were unemployed with the majority also receiving some type of wage replacement (e.g., social security disability, VA service connection). Average pain duration was quite pronounced with an average of 16 years (+8).

With regard to feasibility, two primary results are apparent. First, the trial was under-recruited, as we randomized 29.2% of our intended sample size of 120. There were several factors that decreased recruitment rates, including (1) Veteran hesitation to participate in a trial of behavioral therapy addressing opioid use, (2) the exclusionary criterion of buprenorphine prescription, which was used increasingly over the study period, and (3) the requirement of in-person treatment attendance, which was not feasible for some Veterans, such as those that had to travel long distances to the study facility. Thus, the feasibility of recruitment was less than expected. It may be possible to enhance recruitment through further integration with the UC arm of treatment, which was physician led in the current study and fully independent of the integrated intervention. Such interdisciplinary care is the recommended standard for chronic pain treatment and, for ACT specifically, there is evidence of larger treatment effects for interdisciplinary chronic pain treatment compared with psychology-only for disability, psychosocial impact, and depression (Vowles, Pielech, Edwards, McEntee, & Bailey, in press). Such integrated care may help to allay patient concerns about the possibility that treatment will force opioid dose reduction. Furthermore, the inclusion of patients on buprenorphine or the use of telehealth services may aid in increasing the number of potential participants.

The second result supported feasibility of retention – once patients were assessed for eligibility, a majority were randomized (35 of 42, 83.3%), began the study post-randomization (28 of 35, 80.0%), and provided data at 6-month follow-up (22 of 28; 78.6%). Furthermore, in those randomized to the integrated treatment arm, session attendance was 77% and 13 of 15 participants had attendance rates in excess of 75%.

Outcome analyses for this pilot trial provided initial support for the efficacy of the integrated intervention in comparison to UC alone across the two of the primary outcome
measures, opioid misuse and pain interference with medium to large effect size differences between groups at follow-up. The third primary outcome, pain behavior, was more modestly related to treatment group, with a small between group difference at follow-up. Assignment to the integrated intervention group was associated with lower opioid misuse and pain interference scores at 6-month follow-up in comparison to assignment to the UC group, after controlling for baseline values, baseline prescribed MED, and pain duration. Standardized beta coefficients were statistically significant for group membership in a moderate range (β range: .35 - .45). The pattern of findings was the same for the secondary outcome of pain intensity, but not for MED, which decreased for both groups over the study enrollment period.

As noted above, previous work has examined integrated behavioral treatment for co-morbid chronic pain and opioid misuse. Two recent trials of CBT failed to find evidence of reduction in pain interference\(^5,29\). The successful trials of Garland and colleagues\(^24,25\) did not specifically recruit participants with evidence of ongoing opioid misuse. The results of these intervention trials serve to underscore the complexity in managing co-occurring chronic pain and opioid misuse, where treatment targets include altering responses to persistent pain and opioid use cues, such as withdrawal or opioid craving. At the onset of the present trial, we hypothesized that ACT and MBRP would be particularly well-suited for integration in this clinical population. Each treatment prioritizes effective functioning with ongoing aversive experiences, such as pain and substance craving \(^{39,67}\). These experiences are likely to continue to be a part of living for those with chronic pain who have used opioids in a hazardous manner. Furthermore, both seek to cultivate aspects of present-focused awareness and acceptance in order to facilitate effective responding to ongoing aversive experiences. Finally, each has an established evidence base. While these data are preliminary, they serve to support our hypotheses and suggest that a fully powered trial is worth pursuing.

There are limitations to consider. First, this was a pilot trial intended to primarily test feasibility and provide a preliminary test of efficacy of an integrated behavioral treatment. The
sample size was small, which places limits on generalizability and power. Second, the UC condition did not include a psychotherapy comparator, which means that effects are not necessarily attributable to the integrated treatment and may be due to other non-specific therapeutic factors. Relatedly, we did not collect extensive baseline information in relation to behavioral health diagnoses or pain-related aspects of psychosocial functioning (e.g., pain-related fear). Third, we were able to collect data on prescribed MED only, which is not the same as consumed MED. While opioid dose is likely an important variable, there are also data to suggest that it is potentially more important to examine the manner in which opioids are consumed or the outcomes that patients are intending to achieve through consumption.

Fourth, there was a failure of randomization in that average MED was approximately 25% higher in the treatment group compared to UC. While this difference at baseline between the arms of the study is important, it also potentially means the integrated intervention group was somewhat more complex than individuals in the UC arm. Fifth, as already noted, the study was under-recruited, which indicates poorer than expected feasibility and a need for more effective approaches to enrolling participants into the study. Finally, we did not assess therapist competency in treatment delivery. Such an assessment will be useful to consider in future studies.

In conclusion, chronic pain is a complex health condition that can have multifaceted negative effects on functioning. In at least a proportion of individuals prescribed opioids for the treatment of chronic pain, opioids seem to exacerbate the negative impacts of chronic pain. These individuals require effective intervention for both pain-related interference and problematic opioid use. The present study integrated ACT and MBRP to address this need by training participants to more effectively: (1) notice habitual responding to pain and craving in the present, (2) “make room” for negative feelings and sensations without engaging in ineffective strategies to control them, and (3) engage in personally valued activities to facilitate greater
quality of life. The results of this study provide preliminary evidence that such an approach has promising feasibility and efficacy.
References


9, 2010.


70. Department of Veterans Affairs Opioid Prescribing Data. 2018.
Table 1. Demographic and baseline means (SD) for all randomized participants ($n = 37$).

<table>
<thead>
<tr>
<th>Measure</th>
<th>Total sample</th>
<th>Intervention</th>
<th>UC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>50.5 (10.5)</td>
<td>48.3 (11.6)</td>
<td>53.3 (8.6)</td>
</tr>
<tr>
<td>Pain Duration (yrs)</td>
<td>16.1 (8.4)</td>
<td>14.7 (9.3)</td>
<td>17.8 (7.2)</td>
</tr>
<tr>
<td>Education (yrs)</td>
<td>14.5 (2.1)</td>
<td>14.5 (1.9)</td>
<td>14.5 (2.3)</td>
</tr>
<tr>
<td>Unemployment duration (yrs.)</td>
<td>10.1 (7.4)</td>
<td>9.1 (7.9)</td>
<td>11.3 (6.7)</td>
</tr>
<tr>
<td>Current Opioid Misuse</td>
<td>15.9 (8.6)</td>
<td>15.3 (8.6)</td>
<td>16.7 (7.0)</td>
</tr>
<tr>
<td>Pain Interference</td>
<td>66.3 (5.9)</td>
<td>66.7 (6.0)</td>
<td>65.7 (6.0)</td>
</tr>
<tr>
<td>Pain Behavior</td>
<td>62.7 (4.7)</td>
<td>62.6 (4.1)</td>
<td>62.8 (5.5)</td>
</tr>
<tr>
<td>Pain intensity</td>
<td>6.5 (1.5)</td>
<td>6.4 (1.4)</td>
<td>6.6 (1.6)</td>
</tr>
<tr>
<td>Prescribed Opioid Dose</td>
<td>86.1 (79.9)</td>
<td>99.1 (65.3)</td>
<td>77.0 (58.7)*</td>
</tr>
</tbody>
</table>

*Significant between group difference at baseline indicated.

Measures: Current Opioid Misuse: Current Opioid Misuse Measure, Pain Interference: PROMIS Pain Interference Short Form 8a; Pain Behavior: PROMIS Pain Behavior v1.1 Short Form 7a; Pain Intensity: 0-10 Numerical Rating Scale of Average Pain for Past Week; Prescribed Opioid Dose: Morphine Equivalent Dose for all Prescribed Opioids.
Table 2. Results of Simultaneous Multiple Regression Analyses Predicting 6 Month Follow-up.

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Intent to treat (n = 35)</th>
<th>Per Protocol (n = 28)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Current Opioid Misuse</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>.76**** / .76 (.10)****</td>
<td>.77**** / .76 (.11)****</td>
</tr>
<tr>
<td>MED</td>
<td>.13 / .01 (.01)</td>
<td>.14 / .01 (.01)</td>
</tr>
<tr>
<td>Pain Duration</td>
<td>.03 / .002 (.01)</td>
<td>.03 / .002 (.01)</td>
</tr>
<tr>
<td>Group</td>
<td>.36*** / 5.39 (1.71)***</td>
<td>.36*** / 5.39 (1.56)***</td>
</tr>
<tr>
<td><strong>Model R²</strong></td>
<td>.76 (.08)****</td>
<td>.75 (.12)****</td>
</tr>
<tr>
<td><strong>Pain Interference</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>.55**** / .75 (.27)***</td>
<td>.59*** / .75 (.27)***</td>
</tr>
<tr>
<td>MED</td>
<td>.15 / .02 (.02)</td>
<td>.16 / .02 (.02)</td>
</tr>
<tr>
<td>Pain Duration</td>
<td>.16 / .01 (.01)</td>
<td>.17 / .01 (.01)</td>
</tr>
<tr>
<td>Group</td>
<td>.41*** / 6.50 (2.02)**</td>
<td>.40*** / 6.5 (2.5)**</td>
</tr>
<tr>
<td><strong>Model R²</strong></td>
<td>.54 (.13)****</td>
<td>.56 (.15)****</td>
</tr>
<tr>
<td><strong>Pain Behavior</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>.36* / .39 (.14)**</td>
<td>.34* / .39 (.14)***</td>
</tr>
<tr>
<td>MED</td>
<td>.51**** / .03 (.01)***</td>
<td>.57**** / .03 (.11)***</td>
</tr>
<tr>
<td>Pain Duration</td>
<td>-.10 / -.01 (.01)</td>
<td>-.10 / -.01 (.01)</td>
</tr>
<tr>
<td>Group</td>
<td>.41*** / 4.19 (2.07)*</td>
<td>.42 *** / 4.19 (2.07)*</td>
</tr>
<tr>
<td><strong>Model R²</strong></td>
<td>.37 (.15)*</td>
<td>.36 (.13)*</td>
</tr>
<tr>
<td><strong>Pain Intensity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>.30 / .36 (.21)</td>
<td>.31 / .36 (.21)</td>
</tr>
<tr>
<td>MED</td>
<td>.09 / .002 (.01)</td>
<td>.10 / .002 (.01)</td>
</tr>
<tr>
<td>Pain Duration</td>
<td>.13 / .002 (.003)</td>
<td>.14 / .002 (.003)</td>
</tr>
<tr>
<td>Group</td>
<td>.53**** / 1.94 (.68)***</td>
<td>.54**** / 1.94 (.68)***</td>
</tr>
<tr>
<td><strong>Model R²</strong></td>
<td>.40 (.13)****</td>
<td>.39 (.13)***</td>
</tr>
<tr>
<td><strong>Prescribed Opioid Dose</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>.95**** / .94 (.06)****</td>
<td>.96**** / .94 (.06)****</td>
</tr>
<tr>
<td>Pain Duration</td>
<td>.05 / .04 (.04)</td>
<td>.05 / .04 (.04)</td>
</tr>
<tr>
<td>Group</td>
<td>-.04 / -6.24 (5.76)</td>
<td>-.04 / -6.24 (5.76)</td>
</tr>
<tr>
<td><strong>Model R²</strong></td>
<td>.95 (.02)***</td>
<td>.96 (.02)***</td>
</tr>
</tbody>
</table>

(Table continues)
Table 2. (con’t)

*p ≤ .05, **p ≤ .01, ***p ≤ .005, ****p ≤ .001

Measures: Current Opioid Misuse: Current Opioid Misuse Measure, Pain Interference: PROMIS Pain Interference Short Form 8a; Pain Behavior: PROMIS Pain Behavior v1.1 Short Form 7a; Pain Intensity: 0-10 Numerical Rating Scale of Average Pain for Past Week; Prescribed Opioid Dose: Morphine Equivalent Dose for all Prescribed Opioids.

Group (0=integrated intervention, 1=usual care).
Table 3. Means (SD) for Primary and Secondary Measures for all Completers (n = 22).

<table>
<thead>
<tr>
<th>Group</th>
<th>Baseline</th>
<th>Follow-up</th>
<th>Cohen’s $d$ for</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Integrated vs.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Usual Care at</td>
</tr>
<tr>
<td><strong>Current Opioid Misuse</strong></td>
<td></td>
<td></td>
<td>Follow-up</td>
</tr>
<tr>
<td>Integrated Intervention</td>
<td>16.2 (8.8)</td>
<td>10.6 (6.5)</td>
<td>0.73</td>
</tr>
<tr>
<td>Usual Care</td>
<td>17.4 (7.8)</td>
<td>16.1 (8.5)</td>
<td></td>
</tr>
<tr>
<td><strong>Pain Interference</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Integrated Intervention</td>
<td>66.7 (6.6)</td>
<td>64.3 (9.2)</td>
<td>0.79</td>
</tr>
<tr>
<td>Usual Care</td>
<td>65.2 (6.8)</td>
<td>70.1 (4.9)</td>
<td></td>
</tr>
<tr>
<td><strong>Pain Behavior</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Integrated Intervention</td>
<td>66.7 (6.6)</td>
<td>64.3 (9.2)</td>
<td>0.30</td>
</tr>
<tr>
<td>Usual Care</td>
<td>66.0 (6.6)</td>
<td>66.8 (8.0)</td>
<td></td>
</tr>
<tr>
<td><strong>Pain Intensity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Integrated Intervention</td>
<td>6.6 (1.5)</td>
<td>5.6 (1.9)</td>
<td>1.08</td>
</tr>
<tr>
<td>Usual Care</td>
<td>6.7 (1.8)</td>
<td>7.4 (1.4)</td>
<td></td>
</tr>
<tr>
<td><strong>Prescribed Opioid Dose</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Integrated Intervention</td>
<td>96.4 (70.1)</td>
<td>91.3 (72.1)</td>
<td>0.83</td>
</tr>
<tr>
<td>Usual Care</td>
<td>51.8 (45.6)</td>
<td>41.6 (43.1)</td>
<td></td>
</tr>
</tbody>
</table>

Measures: Current Opioid Misuse: Current Opioid Misuse Measure, Pain Interference: PROMIS Pain Interference Short Form 8a; Pain Behavior: PROMIS Pain Behavior v1.1 Short Form 7a; Pain Intensity: 0-10 Numerical Rating Scale of Average Pain for Past Week; Prescribed Opioid Dose: Morphine Equivalent Dose for all Prescribed Opioids.
Enrollment

85 Phone screened (of 115 referred)

Assessed for eligibility (n= 42)

Excluded (n=7)
- No evidence of opioid misuse (n=5)
- Prescribed suboxone (n=1)
- Outside of age range (n=1)

Randomized (n= 35)

Excluded (n= 43)
- Not meeting inclusion criteria (n= 17)
- Declined to participate (n= 15)
- Other reasons (logistics preclude; n= 11)

Allocation

Allocated to intervention (n= 17)
- Received allocated intervention (n= 15)
  - Did not receive allocated intervention (taken off opioids, n=1; suicide attempt, n=1)
- No response (n=5)

Allocated to control (n=18)
- Received allocated intervention (n=13)

Follow-up (6 month)

Completed (n= 12)
- Lost to follow-up (n = 3)

Completed (n= 10)
- Overdue/Lost to follow-up (n = 3)